Skip to main content

Advertisement

SpringerLink
Log in

Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

We assessed the coverage of sex acts by event-driven pre-exposure prophylaxis (ED-PrEP) over a 2-month period in 54 participants in the open label phase of the ANRS Ipergay trial. Participants received an electronic monitoring system device to record bottle openings. Self-questionnaires collected daily information on PrEP intake and sexual behavior. Intake was also estimated through returned pill counts. Full coverage of sex acts was defined as at least one pill taken both within 24 h before and within 48 h following sex. There was a strong correlation (r =  − 0.92) between the number of bottle openings and returned pill counts. During the study, 42 participants (78%) practiced ED-PrEP and 12 (22%) daily PrEP with bottle openings at least 5 days/week whatever their sexual activity. Out of the 154 reported receptive anal sex acts, 81% were condomless: among them, PrEP coverage was hight: 97% among those practicing daily PrEP and 82% among those using ED-PrEP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  Google Scholar 

  2. Thigpen M, Kebaabetswe P, Smith D, Segolodi T, Soud F, Chillag K, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. In. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011.

  3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  CAS  Google Scholar 

  4. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.

    Article  Google Scholar 

  5. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.

    Article  CAS  Google Scholar 

  6. Lundgren JD, Battegay M, Behren G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. Hiv Medicine. 2008;9(2):72–81.

    Article  CAS  Google Scholar 

  7. WHO. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to WHO’s recommendation on oral PrEP. In; July 2019.

  8. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):291–9.

    Article  CAS  Google Scholar 

  9. Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. Predicting effective truvada (R) PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN). AIDS Res Hum Retroviruses. 2014;30:A60–A6060.

    Article  Google Scholar 

  10. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Inf Dis. 2014;14(9):820–9.

    Article  Google Scholar 

  11. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018;5(2):E68–E78.

    Article  Google Scholar 

  12. Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav. 2015;19(5):794–801.

    Article  Google Scholar 

  13. Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the human immunodeficiency virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2018;66(11):1712–21.

    Article  CAS  Google Scholar 

  14. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. Obstet Gynecol Surv. 2015;70(7):444–6.

    Article  Google Scholar 

  15. Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra14.

    Article  Google Scholar 

  16. Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478–85.

    Article  CAS  Google Scholar 

  17. AARDEX Group, Ltd, Sion, Switzerland. MEMs software: https://www.aardexgroup.com. In.

  18. Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32(1):32–433.

    Article  CAS  Google Scholar 

  19. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. JAIDS J Acquir Immun Def Syndr. 2014;66(3):340–8.

    Article  CAS  Google Scholar 

  20. Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751–9.

    Article  CAS  Google Scholar 

  21. Team RC. R: A language and environment for statistical computing. In. 3.2.3 ed; 2015.

  22. Di Ciaccio M, Fressard L, Sagaon-Teyssier L, Protiere C, Gatey C, Chas J, Cotte L, Castro DR, Meyer L, Molina JM, Préau M, Spire B. What are the situational and behavioral factors associated with condomless anal sex without PrEP in men who have sex with men? Results from the ANRS-IPERGAY trial. AIDS. 2020. https://doi.org/10.1097/QAD.0000000000002542.

    Article  PubMed  Google Scholar 

  23. Molina J, Prevenir ANRS Study G. Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area. Update from the ANRS Prevenir Study. In; 2019 (IAS Mexico).

  24. Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103.

    Article  CAS  Google Scholar 

  25. Vuylsteke B, Reyniers T, De Baetselier I, Nostlinger C, Crucitti T, Buyze J, et al. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc. 2019;22(10):e25407.

    Article  Google Scholar 

  26. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. AIDS. 2018;32(15):2161–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thanks the study participants for their time and dedication to this study, the National Agency for Research on AIDS and Hepatitis (ANRS; France Recherche Nord & Sud Sida-HIV Hépatites) and its Director François Dabis, the Canadian HIV Trials Network, Fondation Pierre Bergé pour la prevention/Sidaction, and the Bill & Melinda Gates Foundation for their grant support, Gilead Sciences for donation of tenofovir disoproxil fumarate and emtricitabine, and Jean-François Delfraissy for his support from the beginning of the trial. We thank the gay communities in France and Canada (AIDES, COQSIDA, REZO) who supported this work.

Funding

The funding was provided by Institut National de la Santé et de la Recherche Médicale [Grant No. N14036LR].

Author information

Authors and Affiliations

  1. Inserm SC10, Villejuif, France

    Rebecca Bauer, Emmanuelle Netzer & Catherine Capitant

  2. Hôpital Saint-Louis, Maladies infectieuses, Paris, France

    Claire Pintado & Jean-Michel Molina

  3. Hôpital de l’Archet, Maladies infectieuses, Nice, France

    Eric Cua

  4. ANRS, Paris, France

    Nicolas Etien & Véronique Doré

  5. Biochimie Et Biologie Moléculaire, Hôpital Lariboisière, Paris, France

    Julien Fonsart

  6. Hôpital Tenon, Maladies infectieuses, Paris, France

    Gilles Pialoux

  7. Hôpital de la Croix Rousse, Lyon, France

    Christian Chidiac

  8. Centre Hospitalier de Grasse, Grasse, France

    Cédric Etienne

  9. Inserm SC10, Université Paris Sud, Université Paris Saclay, Villejuif, France

    Laurence Meyer

Authors
  1. Rebecca Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuelle Netzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire Pintado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine Capitant
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Cua
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicolas Etien
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julien Fonsart
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gilles Pialoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian Chidiac
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cédric Etienne
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Véronique Doré
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Laurence Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jean-Michel Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

ANRS IPERGAY Study Group

Corresponding author

Correspondence to Rebecca Bauer.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauer, R., Netzer, E., Pintado, C. et al. Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial. AIDS Behav 24, 3244–3251 (2020). https://doi.org/10.1007/s10461-020-02890-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-020-02890-6

Keywords

Search

Navigation